HS-20093

P1, N=610, Not yet recruiting, Hansoh BioMedical R&D Company

P2, N=0, Withdrawn, Hansoh BioMedical R&D Company | N=50 --> 0 | Not yet recruiting --> Withdrawn

P2, N=50, Not yet recruiting, Hansoh BioMedical R&D Company | Initiation date: Nov 2023 --> Nov 2024

P2, N=120, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024

P2, N=220, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting

P2, N=170, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting

Particularly promising treatments are enoblituzumab for prostate cancer, 131I-omburtamab for central nervous system malignancies, and HS-20093 for small-cell lung cancer but further studies are warranted. These data will be telling of the efficacy of B7-H3 inhibitors in both hematologic and solid malignancies. This study aimed to compile available results of B7-H3 inhibitors in oncology clinical trials.

P2, N=220, Not yet recruiting, Hansoh BioMedical R&D Company

The addition of an anti-PD-L1, atezolizumab or durvalumab, to platinum/etoposide regimen became the standard of care for first-line therapy of extensive-stage (ES)-SCLC with the 12 months median survival exceeded for the first time. The most promising preliminary clinical results have been reported by DS7300a and HS-20093, both are antibody-drug conjugates, that are under investigation in ongoing trials for the treatment of pretreated SCLC. This review will provide an overview of B7-H3 and corresponding inhibitors and the clinical development in the management of SCLC.

N/A Now the trial is enrolling.

P2, N=170, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting

P1, N=177, Recruiting, Shanghai Hansoh Biomedical Co., Ltd